To use this feature, join Babbler easily !
Babbler allows PR people and reporters to collaborate a better way.
By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.
Their newsrooms are already on Babbler
You're 1 click away from signing up
Nice to see you again !
The Ethypharm Group is strengthening its commitment to pain management through the acquisition of Laboratoires Pharmy II in France
minutes reading time
minute reading time
Saint-Cloud, France – XX April 2019 –
The Ethypharm Group is pleased to announce that a definitive agreement to acquire Laboratoires Pharmy II was signed on 5 April 2019. This acquisition was made with the support of Alira Health.
Based in the Paris region, Pharmy II is a pharmaceutical laboratory. It was founded in France in 1982. Well established in France, the Pharmy II laboratories specialises in the treatment of pain, particularly mechanical musculo-articular pain.
On the French market, it provides healthcare professionals (rheumatologists, mesotherapists, sports physicians), as well as their patients, with a range of solutions designed to be injected locally, using the mesotherapy technique.
Thanks to this acquisition, which is perfectly aligned with the Group’s development strategy, Ethypharm is expanding its portfolio with 6 new drugs and adding pharmaceutical specialities in injectable and liquid form.
Bertrand Deluard, Ethypharm Group CEO, adds: ‘By entering into a new “niche” market, Ethypharm is strengthening its commitment to pain management and its goal of facilitating access to essential medicines for patients around the world.’
Ethypharm is a European-based specialty pharmaceutical company with global reach and is committed to developing innovative drugs for the treatment of pain, addiction and critical care.
Ethypharm develops and markets specialty drugs and generics that provide added value to healthcare providers and delivers high quality medicines for patients.
The Company employs 1400 people mainly in Europe, and its drugs are marketed in more than 80 countries.
Our ambition is to become a European leader in our three core therapeutic areas of pain, addiction and critical care and to expand our presence in new markets in order to facilitate access to essential medicines for patients around the world.
Congratulations, you're registered on Babbler!
Discover now all the news waiting for you on Babbler: visit your newsfeed.!
Your topics have been selected, you can change it by clicking here